Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study

OBJECTIVE: TAS‐102 is effective for treating patients with metastatic colorectal cancer (mCRC). This study determined whether combining bevacizumab (Bmab) with TAS‐102 improves clinical outcomes in refractory mCRC. PATIENTS AND METHODS: We retrospectively analyzed data from Japanese patients with re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Fujii, Hironori, Matsuhashi, Nobuhisa, Kitahora, Mika, Takahashi, Takao, Hirose, Chiemi, Iihara, Hirotoshi, Yamada, Yunami, Watanabe, Daichi, Ishihara, Takuma, Suzuki, Akio, Yoshida, Kazuhiro
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066722/
https://ncbi.nlm.nih.gov/pubmed/32162797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0541
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados